Sofosbuvir plus Peginterferon/Ribavirin for 12 weeks vs. Sofosbuvir plus Ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study

被引：0

作者：

Pianko, S. ^{[1
]}

Cooper, C. ^{[2
]}

Brown, A. ^{[3
]}

Forton, D. ^{[4
]}

Nahass, R. ^{[5
]}

George, J. ^{[6
,7
]}

Barnes, E. ^{[8
,9
]}

Brainard, D. ^{[10
]}

Massetto, B. ^{[10
]}

Lin, M. ^{[10
]}

Mchutchinson, J. ^{[10
]}

Subramanian, G. M. ^{[10
]}

Agarwal, K. ^{[11
]}

Foster, G. ^{[12
]}

机构：

[1] Monash Med Ctr, Melbourne, Vic, Australia

[2] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada

[3] Imperial Coll Healthcare Natl Hlth Serv Trust, London, England

[4] St Georges Univ London, London, England

[5] ID Care, Hillsborough, NJ USA

[6] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2006, Australia

[7] Westmead Hosp, Sydney, NSW, Australia

[8] Nuffield Dept Med, Oxford, England

[9] STOP HCV, London, England

[10] Gilead Sci Inc, Foster City, CA 94404 USA

[11] Kings Coll Hosp London, Inst Liver Studies, London SE5 8RX, England

[12] Queen Marys Univ London, Barts Hlth, London, England

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：90 / 90

页数：1